11-0735
ホルムアルデヒド 溶液
10%
別名:
ホルマリン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
化学式:
HCHO
CAS番号:
分子量:
30.03
PubChem Substance ID:
UNSPSC Code:
41115710
Beilstein/REAXYS Number:
1209228
MDL number:
Vapor pressure:
52 mmHg ( 37 °C)
vapor density
1.03 (vs air)
vapor pressure
52 mmHg ( 37 °C)
form
liquid
autoignition temp.
572 °F
availability
available only in Japan
concentration
10%
dilution
(for analytical testing)
density
1.09 g/mL at 25 °C (lit.)
application(s)
sample preparation
SMILES string
[H]C([H])=O
InChI
1S/CH2O/c1-2/h1H2
InChI key
WSFSSNUMVMOOMR-UHFFFAOYSA-N
Still not finding the right product?
Explore all of our products under ホルムアルデヒド 溶液
signalword
Danger
Hazard Classifications
Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
劇物
pdsc
特定第一種指定化学物質
prtr
名称等を表示すべき危険物及び有害物
ishl_indicated
名称等を通知すべき危険物及び有害物
ishl_notified
11-0735-5-500ML-J:4.54817300767E12
jan
James Larkin et al.
The New England journal of medicine, 373(1), 23-34 (2015-06-02)
Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus
Cindy S Ma et al.
The Journal of experimental medicine, 205(7), 1551-1557 (2008-07-02)
Hyper-immunoglobulin E syndrome (HIES) is a primary immune deficiency characterized by abnormal and devastating susceptibility to a narrow spectrum of infections, most commonly Staphylococcus aureus and Candida albicans. Recent investigations have identified mutations in STAT3 in the majority of HIES
Arpeeta Sharma et al.
Diabetes, 64(11), 3937-3950 (2015-06-28)
Patients with diabetes have an increased risk of developing atherosclerosis. Endothelial dysfunction, characterized by the lowered bioavailability of endothelial NO synthase (eNOS)-derived NO, is a critical inducer of atherosclerosis. However, the protective aspect of eNOS in diabetes-associated atherosclerosis remains controversial